<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Issues</title>
	<atom:link href="http://www.tapanray.in/tag/issues/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Do Drug Companies Now Need More Focus On The 5th &#8220;P&#8221; Of Marketing?</title>
		<link>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing</link>
		<comments>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/#comments</comments>
		<pubDate>Mon, 07 Mar 2022 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[4 Ps]]></category>
		<category><![CDATA[5th P]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driving]]></category>
		<category><![CDATA[Get Z]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[marketing-mix]]></category>
		<category><![CDATA[Millennial]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[purpose-driven marketing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10665</guid>
		<description><![CDATA[Astute marketers understand that over several decades, the much-known phraseology &#8211; ‘marketing mix’, has remained the bedrock of marketing a product or a service. The ‘Father of Modern Marketing’ - Philip Kotler defined this terminology as the &#8220;the set of controllable variables that &#8230; <a href="http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-do-drug-companies-now-need-more-focus-on-the-5th-p-of-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Criticality of Drug Quality In The Moment Of Truth</title>
		<link>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-drug-quality-in-the-moment-of-truth</link>
		<comments>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/#comments</comments>
		<pubDate>Mon, 10 Feb 2020 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['The Moment Of Truth']]></category>
		<category><![CDATA[2019-nCoV]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ARV]]></category>
		<category><![CDATA[CDER]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[dependence]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[letters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Unites States]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[warning]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9870</guid>
		<description><![CDATA[When global health emergencies strike unannounced &#8211; in the scale and magnitude of new coronavirus, it shakes the health care system of all countries, in varying degree though, irrespective of the robustness of the economy. In such situation, the robustness &#8230; <a href="http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-drug-quality-in-the-moment-of-truth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India in The Eye of The AMR Storm?</title>
		<link>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-in-the-eye-of-the-amr-storm</link>
		<comments>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/#comments</comments>
		<pubDate>Mon, 26 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR capital]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Eye of the storm]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[sociocultural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9684</guid>
		<description><![CDATA[‘With 700,000 people losing battle to antimicrobial resistance (AMR) per year and another 10 million projected to die from it by 2050, AMR alone is killing more people than cancer and road traffic accidents combined together.’ This was highlighted in &#8230; <a href="http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sharper Focus On Vaccine: A Huge Scope To Reduce Disease Burden In India</title>
		<link>http://www.tapanray.in/sharper-focus-on-vaccine-a-huge-scope-to-reduce-disease-burden-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=sharper-focus-on-vaccine-a-huge-scope-to-reduce-disease-burden-in-india</link>
		<comments>http://www.tapanray.in/sharper-focus-on-vaccine-a-huge-scope-to-reduce-disease-burden-in-india/#comments</comments>
		<pubDate>Mon, 09 Jan 2017 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[burden]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[GAVI]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[immunization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[prophylactic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[sharper]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8036</guid>
		<description><![CDATA[Several international research studies have conclusively established that the aggressive application of nationally recommended prevention activities could significantly reduce the burden of disease in several areas. Immunization or vaccination program is one such critical areas. Several ailments, which used to &#8230; <a href="http://www.tapanray.in/sharper-focus-on-vaccine-a-huge-scope-to-reduce-disease-burden-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/sharper-focus-on-vaccine-a-huge-scope-to-reduce-disease-burden-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reticence Around Unveiling Clinical Trials</title>
		<link>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reticence-around-unveiling-clinical-trials</link>
		<comments>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/#comments</comments>
		<pubDate>Mon, 17 Oct 2016 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[legalities]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reticence]]></category>
		<category><![CDATA[Semler]]></category>
		<category><![CDATA[statin]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Unveiling]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7886</guid>
		<description><![CDATA[While scanning through various publications, we now get to know, almost at regular intervals, about new clinical trials capturing the newer ways of treating different ailments. Such information instils an invigorating hope in the minds of doctors and the patients &#8230; <a href="http://www.tapanray.in/reticence-around-unveiling-clinical-trials/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reticence-around-unveiling-clinical-trials/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India &#8211; Young Today, Old Tomorrow: Emerging Issues of Aging, Health and Socioeconomic Profile of the Country</title>
		<link>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country</link>
		<comments>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/#comments</comments>
		<pubDate>Sun, 29 Apr 2012 01:30:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[emerging]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Today]]></category>
		<category><![CDATA[Tomorrow]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Young]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=100</guid>
		<description><![CDATA[‘World Health Day’ is celebrated every year on April 7, the day ‘World Health Organization (WHO)’ was founded in 1948. Each year, on this day, people from all walks of life across the globe are invited by WHO to focus &#8230; <a href="http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-young-today-old-tomorrow-emerging-issues-of-aging-health-and-socioeconomic-profile-of-the-country/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmaceutical R&amp;D in India: Issues and Challenges</title>
		<link>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-rd-in-india-issues-and-challenges</link>
		<comments>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/#comments</comments>
		<pubDate>Mon, 15 Aug 2011 00:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=215</guid>
		<description><![CDATA[Research and Development (R&#38;D) initiatives, though very important for most of the industries, is the life blood for the pharmaceutical sector, across the globe, to meet the unmet needs of the patients. Thus, very rightly, the Pharmaceutical Industry is considered &#8230; <a href="http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-rd-in-india-issues-and-challenges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why does the Government divert focus on to fringe issues to address critical healthcare concerns of the nation?</title>
		<link>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation</link>
		<comments>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/#comments</comments>
		<pubDate>Mon, 04 Oct 2010 01:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[address]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[divert]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[fringe]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=366</guid>
		<description><![CDATA[The Department of Industrial Policy and Promotion (DIPP) of the Ministry of Commerce and Industry of the Government of India has recently initiated a public debate through a ‘Discussion Paper on Compulsory Licensing (CL) of Patented Pharmaceutical Products’. The key &#8230; <a href="http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
